<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969254</url>
  </required_header>
  <id_info>
    <org_study_id>E01-OSM-PLS-01-08</org_study_id>
    <nct_id>NCT00969254</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of &quot;Pílulas de Lussen®&quot; Compared to the Pyridium® in the Symptomatic Control of Dysuria</brief_title>
  <acronym>E01OSMPLS0108</acronym>
  <official_title>Phase III Clinical Study, Prospective, Multicenter, Double-blind, Randomized, Double-dummy to Assess the Efficacy and Safety of &quot;Pílulas de Lussen®&quot; Compared to the Pyridium® in the Symptomatic Control of Dysuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Osorio de Moraes Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Osorio de Moraes Ltda.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Study, prospective, comparative, randomized, double-dummy entry with random from a
      total of 80 patients, 40 patients will receive the test medication (Pílulas de Lussen®) plus
      placebo and 40 patients will receive the comparative (Pyridium®) plus placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III Clinical Study, prospective, multicenter, double-blind, randomized, double-dummy to
      assess the efficacy and safety of &quot;Pílulas de Lussen®&quot; compared to the Pyridium® in the
      symptomatic control of dysuria in 80 patients of either sex or race, older than 18 years,
      with symptoms of dysuria, 40 patients will receive the test medication (Pílulas de Lussen®)
      plus placebo and 40 patients will receive the comparative (Pyridium®) plus placebo to
      evaluate the effectiveness and tolerability of 'Pílulas de Lussen' for symptomatic relief of
      dysuria.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogic Scale and opinion of the investigator.</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Of adverse events related to study medication by the Naranjo Algorithm.</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Dysuria</condition>
  <arm_group>
    <arm_group_label>Pílulas de Lussen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.
* Drug A: Pílulas de Lussen®
** Drug B: placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyridium®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.
* Drug A: Pyridium®
** Drug B: placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pílulas de Lussen</intervention_name>
    <description>Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.
* Drug A: Pílulas de Lussen®
** Drug B: placebo.</description>
    <arm_group_label>Pílulas de Lussen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridium®</intervention_name>
    <description>Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.
* Drug A: Pyridium®
** Drug B: placebo.</description>
    <arm_group_label>Pyridium®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over the age of 18 years;

          -  Patients with symptoms of dysuria characterized by pain/burning sensation in the lower
             urinary tract and discomfort in urination;

          -  Patients who are female and are of childbearing age should use reliable method of
             contraception and have negative pregnancy test.

          -  Patients who consent to participate in the study.

        Exclusion Criteria:

          -  Patients with sensitivity to any component of the formula;

          -  Patients pregnant or lactating;

          -  Patients with a history of glaucoma, heart failure, cardiac arrhythmias, prostatic
             hypertrophy, paralytic ileus or pyloric stenosis;

          -  Patients with menorrhagia or heavy menstrual periods;

          -  Patients who need to use antibiotics or chemotherapy;

          -  Patients who can not follow the procedures shown in this Clinical Protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lúcia Hime</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade de Santo Amaro (UNISA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nabil Ghorayeb</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Nabil Ghorayeb</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrícia Smith</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Nabil Ghorayeb</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ceci Lopes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dagoberto Brandão</last_name>
    <phone>55 11 3673 3763</phone>
    <email>dagoberto@phcbrasil.com.br</email>
  </overall_contact>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2009</study_first_posted>
  <last_update_submitted>August 31, 2009</last_update_submitted>
  <last_update_submitted_qc>August 31, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Maria Angelina Nardy Mattos</name_title>
    <organization>Laboratórios Osório de Moraes Ltda.</organization>
  </responsible_party>
  <keyword>Pílulas de Lussen</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Dysuria</keyword>
  <keyword>Symptomatic control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

